Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Novartis AG is placed ninth on our list among the best cancer stocks.

TheFly reported on January 6 that Barclays upgraded NVS to Equal Weight from Underweight with a CHF 120 price target after a coverage transfer. Barclays noted a poor operational outlook for 2026 and stated that the company’s “fairly rich” pipeline is mostly reflected in valuation and faces competition.

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

In other news, Novartis AG (NYSE:NVS) unveiled a 35,000-square-foot RLT facility in Winter Park, Florida, on January 9. This is the company’s fourth U.S. location and a component of its $23 billion U.S. investment strategy. The facility handles specific, time-sensitive logistics and was built to support precision oncology treatments such as Pluvicto and Lutathera.

Novartis AG (NYSE:NVS) is a global biopharmaceutical leader with a robust oncology portfolio, including over 30 high-value therapies and a growing radioligand therapy (RLT) pipeline. The company invests heavily in precision oncology, advanced manufacturing, and targeted treatments like Pluvicto and Lutathera to address complex cancer needs worldwide.

While we acknowledge the risk and potential of NVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.